Hryz Bio Tech

, dba Hryz Bio Tech, is a biotechnology company focused on the development of immune cell therapy technology for solid tumors. The company is headquartered in Shanghai and has wholly-owned subsidiaries in Shenzhen and Guangzhou. It has applied for 46 patents of various types and has been granted 15 authorizations through PCT applications in China, the United States, Japan, Russia, and Israel. It has 10 doctoral talents, more than 50 master talents and 7 returnees. Furthermore, it passed ISO9001, ISO14001 and OHSAS18001 management system certifications in 2016 and is building a headquarters base in Songjiang, Shanghai and a regional cell preparation center in the Yangtze River Delta in 2021. Based on the Reverse Genetic Engineering TCR Screening Technology Platform (ReGET), Hryz Bio Tech develops MASCT (Multi-Antigen Stimulated Cell Therapy Injection) products, TCR-T (T Cell Receptor-Gene Engineered T Cells) immune cell products, and TCR dual antibody products. Its TCR-T product HRYZ-T101 can be used to treat cervical cancer.

1. Series C

   Jan 9, 2024

   Amount

   $14M

   Investors

   Locked

2. Series C

   May 12, 2023

   Amount

   $29M

   Investors

   Locked

3. Series B

   Dec 28, 2020

   Amount

   Undisclosed

   Investors

   Locked

4. Series A

   Sep 2, 2020

   Amount

   Undisclosed

   Investors

   Locked